Table 1.

Summaries for 24-week changes from baseline for the various measures. (D_ denotes differences between current and baseline values).

Training Difference DataMean (SE)t-valueUnadjustedZ-value forEffect SizeSRMGESGUES
OROR
(change from baseline)PlaceboDrugDrug vs PlaceboDrug vs PlaceboDrug vs PlaceboPlaceboDrugPlaceboDrugDrug vs Placebo
D_TJC68−4.066 (0.824)−10.693 (0.835)−5.640.955−5.19−0.2594−0.7661−0.3390−0.8430−0.5362−0.8914
D_SJC66−2.854 (0.572)−6.368 (0.548)−4.440.946−4.17−0.2800−0.6793−0.3429−0.7644−0.4220−0.7651
D_HAQ−0.118 (0.029)−0.477 (0.034)−7.950.183−6.88−0.2178−0.7462−0.2859−0.9162−0.7583−1.1519
D_CRP−0.043 (0.104)−1.281 (0.158)−6.440.611−5.79−0.0662−0.5263−0.0286−0.5370−0.6155−0.8523
D_logCRP−0.075 (0.058)−1.393 (0.087)−12.440.315−9.15−0.0992−1.0721−0.0893−1.0652−1.1894−1.6600
D_MDGDA (Likert)−0.333 (0.065)−1.329 (0.069)−10.370.360−8.37−0.5023−1.8403−0.3546−1.2689−0.9983−1.4138
D_PtGDA (Likert)−0.081 (0.068)−1.069 (0.077)−9.550.426−7.99−0.1123−1.1643−0.0810−0.9168−0.9090−1.0753
D_Patient assessment of pain (Likert)−0.109 (0.071)−1.165 (0.081)−9.720.435−8.07−0.1708−1.3199−0.1059−0.9443−0.9255−1.1313
D_SF-36PCS*1.544 (0.621)9.636 (0.672)8.821.0967.470.15730.96880.17120.96180.84781.0685
D_SF-36 MCS*0.317 (0.763)2.492 (0.656)2.311.0232.290.09830.22200.03240.25510.22250.2548
  • * Improvement over time is indicated by a positive increase in the score, as compared to the other measures where a decrease indicated improvement. SRM: Standardized response mean; GES: group effect size; GUES: Guyatt’s effect size; TJC: tender joint counts; SJC: swollen joint counts; HAQ: Health Assessment Questionnaire; CRP: C-reactive protein; MDGDA: physician global assessment of disease activity; P+GDA: patient global assessment of disease activity; SF-36 PCS: Medical Outcomes Study Short-Form physical component; SF-36 MCS: SF-36 mental component.